Stay updated with breaking news from Morphosys Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference12.12.2021 / 15:00 The issuer is solely responsible for the content of this announcement.MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Data presented during poster...
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous29.11.2021 / 22:02 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 29, 2021MorphoSys AG: Corporate Calendar 2022 Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follow...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follows:Publication of Interim Statement / ReportConference
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4